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tive methods was same. There was only 9% of the illiterate workers were using
while the usage compliance increased to 28%. Gender based analysis suggests that
the women workers were less aware about silicosis disease and less educated -
these could be reasons for women workers for less likely use protective methods.
CONCLUSIONS: Awareness is important for the health safety, but the understand-
ing and education level of workers is key factors, these data suggest that not just
the awareness, but also the education level of workers plays a significant role in
compliance toward the usage of protective methods.
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OBJECTIVES: To examine characteristics of US patients with emergency depart-
ment (ED) visits or hospitalization for anaphylaxis, and the cost drivers of these
visits. METHODS: This retrospective study utilized the MarketScan® claims data-
bases to identify patients enrolled in employer-sponsored health plans and visited
EDs or hospital with anaphylaxis between 2002 and 2008. Patients had to have 1
year continuous health coverage pre- and post-index (first observed event date)
and were excluded if immunocompromised, had pre-index cancer diagnoses or
sepsis at index. Descriptive statistics were evaluated for patient characteristics
during the pre-index period and for costs of index events. Multivariate analyses
were conducted examining cost drivers of index events. RESULTS: A total of 11,972
patients were identified (mean age 42, children 19%; female 59%; Northeast 12%;
triggers: unknown cause 66%, food 20%, venom 8%,medicine 6%), and themajority
of events occurred in ED (78%). Compared to adult patients, children (18 years)
weremore oftenmale (56 vs. 38%), and had different pre-index comorbidities (4 vs.
1 of 5 most prevalent comorbidities were allergy-related). Mean index event costs
were $1553  1705 for ED visits and $14262  36108 for hospital stays. Unadjusted
ED costs for children did not differ across triggers (P0.78), but hospitalization costs
did (P0.001). For adults both ED and hospital event costs differed by trigger
(P0.001). In multivariable analyses unknown and venom triggered event costs for
adults were 1.13 (P0.03) and 1.34 (P0.01) times greater than those for children
regardless of place of service. Overall, pre-index epinephrine auto-injection device
(EAID) fill was associated with lower event cost (0.89 times; 95% CI 0.83-0.95).
CONCLUSIONS: This study found significant differences in clinical characteristics
and costs by age group, trigger, and treatment setting among patients with ana-
phylaxis. Pre-index EAID fill may be associated with lower ED/hospitalization cost,
but needs confirmation in future studies.
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AMONG UNIVERSITY STUDENTS IN PAKISTAN
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OBJECTIVES: To evaluate the prevalence of smoking behavior among university
students in Pakistan. METHODS: The cross-sectional study was conducted in two
provinces, KPK and Punjab of Pakistan. Only smoking students’ population of the
universities were included. Six univerties were included in the study from four
cities of these two provinces. These cities were selected for study as they can
provide ethnic mix of student response residing in these areas. A total of 750
questionnaires were administered out of which 524 questionnaire were received
giving the response rate of 69.8% of which 419 were males and 105 were females
from different universities. RESULTS: Among 524 respondents, 419 were male and
105 were female students. Students were recruited regarding socio-demographic
factors, smoking history of students, their families, friends and class fellows/room-
mates and place of residence. Students having family history of smoking (23.87% of
males; 34.29% of females), roommates (21% of males; 5.71% females), close friends
(57.51% of males; 54.28% of females) and class fellows (37.23% of males; F36.19%
of females) were significantly associatedwith smoking. Public health awareness on
media and warnings printed on tobacco products (cigarettes and flavors) had no
statistically significant association with respondents’ continuation, and cessation
status. CONCLUSIONS: The Shisha smokers thought that shisha smoking is less
harmful than cigarette smoking. It is suggested that the factors which influence
Pakistani students to smoke may not be significantly different from counties with
a broader evidence base. There is a need to adopt the provisions of the Framework
Convention on Tobacco Control (FCTC) with respect to smoke free places, public
education and treatment for tobacco cessation. Steps should betaken by the gov-
ernment to increase people’s awareness on the health hazards of tobacco smoking
(Shisha and cigerretes) and to prevent young generation from smoking.
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OBJECTIVES: The study evaluated predictors of willingness to quit smoking among
cigarette smokers in India.METHODS: A cross-sectional study using a self-admin-
istered questionnaire was conducted in a cohort of adults aged 18 years in India.
The outcome variable, willingness to quit smoking was dichotomized. Indepen-
dent variables included socio-demographic characteristics, behavioral and envi-
ronmental determinants of smoking like past quit attempts, smoking status of
peers and social pressure. SAS(9.2v) was used to determine frequencies and chi-
square analyses followed by Fisher’s exact test and stepwise logistic regression to
determine predictors of willingness to quit. RESULTS: The study cohort consisted
of 456 smokers (response rate 41.3%) among which 253 (54%) were willing to quit
smoking. Almost 60% of smokers willing to quit weremales, 53.3% had a bachelor’s
degree, 81.4% were married, 46.6% belonged to the $10,000/yr-$20,000/yr in-
come category and 43.8% to 30-39 years age category. More than 50% had non-
smoking peers. Majority (88.8%) had very low addiction levels and 40% attempted
to quit at least once in their lifetime. Bivariate analysis indicated that age (p0.002),
education (p0.009), siblings’ smoking status (p0.0001), number of smoking
friends (p0.0001), age of initiation (p0.03), past quit attempts (p0.0001) and
social pressure (p0.006) were associated with willingness to quit. Fisher’s exact
test demonstrated that past quit attempts of 3 (p0.0001; OR2.55; 95%CI1.59-
4.06) or 4 (p0.0001; OR33.14; 95%CI7.87–139.63), close friends (p0.002;
OR1.86; 95%CI1.24-2.75), siblings being non-smokers (p0.001; OR3.05;
95%CI2.07–4.45), and few smoking friends (p0.001; OR2.81; 95%CI1.73–4.56)
were predictors of willingness to quit. Logistic regression indicated that smokers
aged 40-49 (p0.02; OR2.06; 95%CI1.13-3.75), 50-59 years (p0.02; OR9.43;
95%CI1.13-79.87), and faced with social pressure (p0.02; OR2.05; 95%CI1.07-
3.9) were willing to quit. CONCLUSIONS: Research on interventions targeting
smokers willing to quit such as those facing social pressure or older smokers,
would prove beneficial for them to permanently quit smoking.
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THE TRENDS OF CHILD OBESITY AND THE EFFECT OF CHILD OBESITY ON
ASTHMA IN YOUNG CHILDREN
Chung J, Nichol MB
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OBJECTIVES: The objectives of this study were to examine the trends of child
obesity and changes in BMI over time and to analyze the effect of child obesity on
asthma.METHODS: The Early Childhood Longitudinal Study Kindergarten Class of
1998-99 (ECLS-K) data from the U.S. Department of Education identified 14,188
children in the 3rd grade who were followed through 3 waves (3rd, 5th and 8th
grade). Dichotomized weight group (obese vs. non-obese), based on body mass
index (BMI) using the 2000 sex-specific CDC growth charts for the United States,
was included in the sampleweight-adjusted cross-sectional logistic analyses and a
panel fixed effects (FE) model for having asthma. RESULTS:We detected a gradual
increase in the mean BMI and prevalence of obesity over time. Significant differ-
enceswere observed for obesity and asthma rate amongmale and female groups in
the 3rd grade (p0.05). In cross-sectional analyses, obesity and gender were signif-
icantly associated with having asthma for each grade level while adjusting for
other demographic covariates (all p0.05), indicating that children who are obese
or male were more likely to have asthma. Approximately 70% of children stayed
within the same weight category from 3rd to 8th grade. FE model showed a signif-
icant time effect where odds of having asthma increased 3.31 times from 3rd to 5th
grade while controlling for child obesity (95% CI: 2.89-3.80). Child obesity and the
interaction term between time effect and child obesity had no significant effect on
asthma although the sign of estimate for child obesity indicated an increase in risk
for asthma. CONCLUSIONS: We found a risk association between child obesity
and asthma in cross-sectional analyses but the effect of obesity on asthma was
not significant in a panel data FE model. Future research with a model using an
instrumental variable is warranted to control for endogeneity associated with
obesity.
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OBJECTIVES: Chronic Obstructive Pulmonary Disease (COPD) is a major public
health issue and a leading cause of morbidity and mortality in the United States.
High frequency of exacerbations can lead to rapid decline in lung function in COPD
patients. The study objective was to evaluate 30-day readmission rates among
COPD patients who received arformoterol, a nebulized long-acting beta agonist, or
nebulized short-acting beta agonists (neb-SABA) during an inpatient stay.
METHODS: Data from the Premier Database, a US nationally representative hospi-
tal database, were used. The study included adult inpatients aged 40 and older,
discharged between January 2006 and March 2010, having a principal diagnosis
code for COPD (ICD-9-CM 491.xx, 492.xx, 496) or secondary COPD diagnosis with a
principal respiratory diagnosis. Patients receiving arformoterol daily on 80% of
days following initiation were compared to patients receiving only neb-SABA dur-
ing hospitalization. Arformoterol patients were matched 1:2 with Neb-SABA pa-
tients on age, gender, severity of illness, and principal/secondary COPD diagnosis.
Chi-square tests were used to evaluate differences in unadjusted readmission
rates. Multivariate logistic regression was performed, adjusting for age, gender,
race, admission type, severity, principal/secondary COPD diagnosis, use of other
respiratory drugs and respiratory therapy, oxygen use, and hospital size and teach-
ing status. RESULTS: The final sample included 812 arformoterol patients and 1651
Neb-SABA patients who had not died during the initial COPD visit. ICU use, which
was not a match criterion, was greater among arformoterol patients (35.5% vs.
19.9%, p0.0001), possibly indicating greater disease burden. Unadjusted readmis-
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sions were significantly lower for arformoterol patients than Neb-SABA patients
(8.7% vs. 12.1%, p0.0169). Adjusted odds of readmission were estimated to be 44%
less for arformoterol patients (OR 0.56, 95% CI 0.41-0.78). CONCLUSIONS: All-cause
30-day readmissions were significantly fewer for arformoterol patients than neb-
SABA patients, both before and after adjusting for patient and hospital factors such
as ICU care.
RESPIRATORY-RELATED DISORDERS – Research on Methods
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IS IT APPROPRIATE TO MEASURE ASTHMA CONTROLLER ADHERENCE USING
PHARMACY CLAIMS DATA?
Visaria J, Frazee SG, Henderson RR
Express Scripts, Inc., St. Louis, MO, USA
While possession-based adherence measures are typically used to compare med-
ication adherence using pharmacy claims, thesemeasures are difficult to verify for
inhaled asthma medications because the claim-reported days’ supply may not
reflect the actual duration of use. OBJECTIVES: To compare medication adherence
to all asthma controllers to that in subsets of patients using Flucitasone/Salmeterol
disk with inhalation device (combination inhaler, CI) or leukotriene inhibitors (LT)
which are more likely to accurately reflect days’ supply in the claim, across phar-
macy dispensing channels. METHODS: Commercially insured US patients aged
12-63 and medically diagnosed for asthma were followed for one year after initia-
tion of an asthma controller using a retrospective, claims-based design. Adherence
was defined using Medication Possession Ratio (MPR). CI and LT subsets included
all patients using one of these as the indexmedications. Themultivariate-adjusted
relationship between adherence and channel was evaluated using a generalized
linear model. RESULTS: A total of 6014 patients were included in the overall study
cohort, with 2222 in theCI subgroup and 1884 in the LT subgroup. The adjustedMPR
for asthma controllers in the retail pharmacy cohort was 39.70% (95% CI 37.08-
42.52%) compared to 62.43 (95% CI 58.19-66.97%) in the mail-order cohort. In com-
parison, the adjusted MPR for retail andmail-order pharmacy cohorts were 38.33%
(95% CI 34.58 - 42.49%) and 57.85 (95% CI 52.13-64.20%) in the CI subgroup and
49.01% (95% CI 43.83-54.79%) and 69.25 (95% CI 52.13-77.56%) in the LT subgroup,
respectively. CONCLUSIONS: In a large, nationally representative cohort, adher-
ence to asthma controllers and differences in adherence across dispensing chan-
nels were similar inmagnitude to those in two subgroups withmore accurate days
supply information. It may be reasonable to use possession-based asthma adher-
ence measures derived from pharmacy claims, despite potential errors in captur-
ing days’ supply.
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COMPARISON OF RISK ADJUSTMENT MODELS IN PREDICTING DISEASE
SPECIFIC AND TOTAL HEALTH CARE EXPENDITURE FOR COPD
Patel JG, Johnson ML, Aparasu RR
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OBJECTIVES: To compare and determine the best risk adjustment model for pre-
dicting disease specific and total health care expenditure associated with Chronic
Obstructive Pulmonary Disease (COPD). METHODS: Data from 2005-2008 Medical
Expenditure Panel Survey, involving adults 18 years with COPD diagnosis were
used to evaluate risk adjustment measures. The outcomes of COPD specific health
care expenditure, total inpatient expenditure, total outpatient expenditure and
total health care expenditure weremodeled using linear regression. Baseline char-
acteristics included age, gender and race. The six different risk adjustment mea-
sures compared were total number of medications, total number of respiratory
medications, D’Hoore-Charlson, Deyo-Charlson, modified Elixhauser and General
Health Status (GHS). Different combinations of thesemeasures were used to derive
the best risk-adjustment model having the highest Adjusted-R2. Validation of the
risk adjustment measures was performed on 2009 MEPS data. RESULTS: Of the six
risk adjustment measures, the total number of respiratory medications performed
best for predicting COPD specific expenditure (Adj. R2: 24.62%). The total number of
medications best predicted inpatient, outpatient and total health care expendi-
tures (Adj. R2: 17.71%, 6.44% and 32.71% respectively). No combination of risk ad-
justment models led any improvement in predicting COPD specific health care
expenditures. The combination of count of all medications with modified Elix-
hauser index performed best in predicting inpatient, outpatient and total health
care expenditure (Adj.R2: 18.44, 7.91 and 34.87 respectively). CONCLUSIONS:Num-
ber of respiratory medications may be an indicator of severity of the disease,
thereby best predicting the disease specific health care expenditure, where as sim-
ple construct of count of all medications used is the best predictor of total health
care expenditure. Medication-based measures can be effective and easy to use in
risk-adjusting health care expenditures.
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OBJECTIVES:Medical interventions are often administered as treatment combina-
tions (e.g., drug A  drug B). Models for effects of treatment combinations in mul-
tiple treatment comparison meta-analysis (MTCs) have previously been proposed.
The objective of this studywas to evaluate the comparative statistical performance
of the conventional MTC model and an ‘additive effects’ MTC model, in scenarios
where ‘additivity’ holds true (i.e., where the effect of effect of treatment A and B
combined is equal to the sumof the individual effects of treatmentA and treatment
B) and in scenarios where ‘additivity’ is mildly or strongly violated.METHODS:We
simulated MTC scenarios where additivity held true or was violated. We applied
conventional and additive effects Bayesian MTCmodels to the simulated data. We
measured the proportion of over- and underestimated treatment effects, the cov-
erage of the 95% credible intervals, and the statistical power. RESULTS: Under true
additivity, the additive effects model is superior to the conventional model. Under
mildly violated additivity, the additive model is less accurate (more over- and
underestimates), but more precise (comparable coverage and greater power). Un-
der strongly violated additivity, the additive model performs worse in terms of
accuracy and coverage. CONCLUSIONS: The additivemodel may readily be used in
practice when approximate additivity can be assumed.
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OBJECTIVES: The Urticaria Patient Daily Diary (UPDD), originally developed in pa-
per format, has beenmigrated to an electronic version. This study was designed to
assess the test-retest reliability of the electronic version (ePRO) of the UPDD.
METHODS: The UPDD includes a morning component, assessing CIU symptoms
and impact on sleep, and an evening component, assessing symptoms, impact on
daily activities, rescue medication use, and contacting a health care provider.
Adults and adolescents with moderate to severe chronic idiopathic urticaria (CIU)
completed the morning and evening ePRO UPDD once, engaged in an hour-long
filler task (Sudoku puzzles), and then completed the UPDD again. Test-retest reli-
ability between the two UPDD completions was assessed by item using a weighted
Kappa, a simple Kappa for a dichotomous item (angioedema), and McNemar’s test
for one item (calling a doctor/nurse). Intraclass correlation coefficients (ICCs) as-
sessed the reliability of the Urticaria Activity Score (UAS), which is the sum of the
‘itch severity’ and ‘number of hives’ item scores. RESULTS: Forty-five patients aged
13 to 74 years (mean 43.6 years) with stable symptoms at time of diary completion
participated. Kappa values ranged from 0.83 to 1.00 for the ePRO UPDD items. The
McNemar’s test yielded a non-significant p-value (p 0.317). For the UAS, ICC was
0.83 for the morning ePRO UPDD and .96 for the evening ePRO UPDD; each of the
Wilcoxon p-values was greater than 0.05. CONCLUSIONS: All Kappas were above
the 0.74 threshold (Coons et al, 2009), indicating excellent test-retest reliability. No
significant differenceswere found between test and retest scores on the UAS or the
‘contacting health care provider’ item. In summary, the ePRO UPDD showed excel-
lent test-retest reliability in a sample of CIU patients whose symptoms were stable
at time of UPDD completion.
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ACCEPTABILITY OF THE SELF-ADMINISTERED COMPUTERIZED (SAC) VERSIONS
OF THE BASELINE/TRANSITION DYSPNEA INDEXES (BDI/TDI) FOR PATIENTS
WITH COPD FROM SEVEN COUNTRIES
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OBJECTIVES: The original interviewer-administered versions of the Baseline/Tran-
sition Dyspnea Indexes (BDI/TDI) were modified by the originator to create self-
administered and computerized (SAC) versions. The rationale for the development
of the SAC versions was to offer a standardized method for patients to report the
impact of activities of daily living on the severity of their breathlessness. The
objective of this study is to present the acceptability of the SAC versions of the
BDI/TDI to patients with COPD from seven countries including eight different lan-
guages [Dutch (The Netherlands), English (Canada, UK), Flemish (Belgium), French
(Belgium, Canada), German (Germany), and Spanish (Spain)]. METHODS: A stan-
dardized methodology was followed to translate the SAC BDI/TDI (e.g., forward/
backward step, review by author). The test on 5 COPD patients in each country was
conducted in form of in-depth interviews to evaluate 1) comprehension, and 2)
acceptability using laptop computers. RESULTS: Overall, most patients liked the
SAC versions, and about half preferred it to a interviewer-administered question-
naire. Only four of 35 patients had problems using the mouse to click on the right
answer for the BDI (e.g., difficulties of coordination, or in using the left button). The
items were understood with no difficulties; themain challenging issue was ease in
understanding the equivalents of “Baseline” and “Transition”. At first, 42% of the
patients, especially in Germany (4/5 patients), Spain and UK (3/5 patients), had
difficulties with the instructions to select answers on the TDI using the up-and-
down elevator buttons. These difficulties did not persist after the practice question
designed to help the patients to become familiar with clicking an “X” (BDI), and using
the up-and-down arrows (TDI). CONCLUSIONS: The SAC versions of the BDI/TDI
were well accepted by patients from seven different countries. Special attention
and supervision should be given to patients not familiar with computer use.
PRS55
A NEW CONCEPT OF PATIENT REPORTED OUTCOME ON QUALITY INDICATORS
FOR PHARMACEUTICAL CARE
Huttin C
ENDEPUSresearch and ENDEPResearch Group, Cambridge, MA, USA
OBJECTIVES: A new concept of Patient-Reported Outcome (PRO) on quality indica-
tors for pharmaceutical services is presented. It aims to supplement postmarketing
surveillance tools. It is based on research findings fromapatient survey instrument
designed at Harvard and applied to a Primary Care Group in Warwickshire, as a
quality improvement tool (Value inHealth, vol 5, issue 3, 2002). AHRQ considers the
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